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Abstract 
Background: Management of schizophrenia is sub‑optimal in many patients. Targeting negative symptoms, among 
the most debilitating aspects of schizophrenia, together with positive symptoms, can result in significant functional 
benefits and dramatically improve quality of life for patients and their carers. Cariprazine, a partial agonist of the 
dopamine receptors D2/D3 has demonstrated effectiveness across symptom domains in clinical trials, particularly on 
negative symptoms.
Objective: To obtain a broader insight from clinicians with specific experience with cariprazine, on how it affects 
patient populations outside the clinical trial setting.
Methods: The panel addressed a series of psychopharmacologic topics not comprehensively addressed by the 
evidence‑based literature, including characteristics of patients treated, dosing and switching strategies, duration 
of therapy, role of concomitant medications and tolerability as well as recommendations on how to individualize 
cariprazine treatment for patients with schizophrenia.
Results: Patients recommended for cariprazine treatment are those with first episodes of psychosis, predominant 
negative symptoms (maintenance/acute phase) and significant side effects (metabolic side effects, hyperprolactine‑
mia, sedation) with other antipsychotics. When the long‑term treatment of a lifetime illness is adequately weighted, 
cariprazine becomes one of the first‑line medications, not only for patients with predominant negative symptoms but 
also for those with relatively severe positive symptoms, especially if they are at the first episodes and if a specific medi‑
cation is added for symptoms such as agitation or insomnia. For instance, patients with agitation may also benefit 
from the combination of cariprazine and a benzodiazepine or another sedating agent. Cariprazine may be prescribed 
as add‑on to medications such as clozapine, when that medication alone is ineffective for negative symptoms, and 
sometimes the first may be discontinued or its dose lowered, after a period of stability, leaving the patient on a better 
tolerated antipsychotic regimen.
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Introduction
What do King Henry VI and the Nobel laureate John 
Nash have in common? Both were thought to have had 
schizophrenia. While the term schizophrenia is less 
than 100 years, it was first identified as a discrete men-
tal illness  in 1887 and is believed to have accompanied 
mankind through its history [1, 2]. Schizophrenia is a 
complex heterogenous, stigmatised mental disorder with 
multiple domains of presentation and a highly variable 
clinical course that can devastate individuals and fami-
lies. It affects approximately 1% of the general popula-
tion with an estimated 20 million cases worldwide [3, 
4]. Treatment modalities in schizophrenia have changed 
fundamentally in recent decades and fortunately the days 
of people with the disease being confined to treatment in 
asylums are far behind us. We now have a range of antip-
sychotic agents and rehabilitation strategies with proven 
efficacy in treating symptoms and behaviours associated 
with the disorder [5]. However, there are still treatment 
gaps—with one source indicating that only about half of 
all patients with schizophrenia receive treatment [6].
For instance, the clinical manifestations of schizophre-
nia are heterogeneous and this makes it difficult to estab-
lish the effectiveness of specific treatments in a group of 
patients presenting with quite diverse clinical manifesta-
tions. Also, more than half of patients with schizophre-
nia experience negative symptoms, which are connected 
with significant treatment challenges [7]. In fact, nega-
tive symptoms have been associated to worse treatment 
response and poor functional outcomes compared with 
individuals without negative symptoms [8].
Domains of presentation in schizophrenia include 
positive, negative and emotional symptoms as well as 
cognitive and social functional deficits. Generally, antip-
sychotic agents are most effective in treating the positive 
symptoms of schizophrenia and less successful in treating 
the negative symptoms and cognitive disabilities. Target-
ing negative symptoms (apathy, lack of emotion, alogia, 
anhedonia, and poor social functioning) can result in 
significant functional benefits and dramatically improve 
quality of life of patients and their carers [9]. Indeed, 
the evidence underscoring the importance of negative 
symptoms’ resolution has quickly grown, paralleling the 
growing interest in functional recovery and the observa-
tion that resolution of positive symptoms is not sufficient 
alone to lead to functional recovery, with full functional/
social recovery occurring in 15% or less of patients with 
schizophrenia, with negative symptoms playing a key role 
[9].
Despite the complexity and heterogeneity of schizo-
phrenia, the reduction of D2-like receptor mediated 
neurotransmission was regarded to be the fundamen-
tal mechanism of antipsychotic action. However, recent 
studies have proposed that alteration in the glutamate, 
GABA, acetylcholine, and serotonin system may play 
a role in the pathology of schizophrenia and a revised 
dopamine hypothesis suggests a role of both hyperac-
tive dopamine transmission in the mesolimbic areas and 
hypoactive dopamine transmission in the prefrontal cor-
tex [10]. To this end partial agonism as well as the differ-
entiated recognition of the D2-like dopamine receptors 
provide a promising approach for treatment of schizo-
phrenia [11]. Cariprazine, a partial agonist of the dopa-
mine receptors receptor and—with higher affinity—of 
the D3-receptor, was approved by the US Food and Drug 
Administration and the European Medicines Agency, for 
the management of schizophrenia based on an extensive 
clinical trial programme demonstrating its effectiveness 
particularly on negative symptoms and its safety [12, 13]. 
Since its approval the exposure to cariprazine is around 
50,000 patient/treatment/year [14].
Cariprazine is pharmacodynamically and pharmacoki-
netically distinct from other oral antipsychotics in that 
it has two active metabolites which contribute to its effi-
cacy and tolerability—the parent drug and the desme-
thyl cariprazine (DCAR) metabolite are responsible for 
early efficacy and side effects, while the second metabo-
lite didesmethyl cariprazine (DDCAR) with its extended 
half-life is primarily responsible for later efficacy and tol-
erability issues [15–17].
Optimal management requires accurate patient charac-
terization and the heterogeneity of schizophrenia means 
that subjects included in clinical trials may not be entirely 
representative of real-world patients [18]. We now know 
that clinical trial data alone may not accurately reflect 
how a drug will behave long-term in a larger, less homog-
enous patient population. Real-world experience pro-
vides a broader insight into the how a product will affect 
patient populations outside the clinical trial setting. With 
this in mind, a group of European psychiatrists (chosen 
Conclusions: Based on real‑world clinical experience, the panel considered that cariprazine, with its distinct advan‑
tages including pharmacokinetics/pharmacodynamics, good efficacy and tolerability, represents a drug of choice in 
the long‑term management of schizophrenia not only for patients with predominant negative symptoms but also for 
those with positive symptoms.
Keywords: Schizophrenia, Antipsychotics, Cariprazine, Patient subgroups, Recommendations, Negative symptoms
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from a range of EU countries, where health systems and 
prescribing habits vary widely), met in December 2019 
to present and discuss their clinical experience with 
cariprazine.
Our hypothesis was that specific treatment algo-
rithms could be suggested based on the characteristics 
of patients treated, for instance to establish dosing and 
switching strategies, duration of therapy, role and type 
of concomitant medications and strategies to improve 
tolerability. We also hypothesized that it was possi-
ble to develop a consensus on the recommendations to 
individualize cariprazine treatment for patients with 
schizophrenia.
This statement represents the panel’s collective experi-
ence, opinions, evaluation, and rationale for the inclusion 
of cariprazine in the management algorithm for medica-
tion treatment of schizophrenia.
Methodology
This was a descriptive survey of a panel of clinicians and 
researchers with extensive experience in the management 
of schizophrenia in general and the use of cariprazine 
in particular. The panel focused on a series of psychop-
harmacologic topics not comprehensively addressed by 
the evidence-based literature but beneficial to clinicians 
prescribing antipsychotic medications and caring for 
patients with schizophrenia. The process took the form 
of the following steps. First, a group of clinicians and 
clinical researchers practicing in Europe or in the United 
Kingdom were surveyed about their ability and willing-
ness to provide clinical experience, scientific background 
and decision-making authority to supply real-world 
experience with cariprazine. Second, one of the clini-
cians (AF) drafted a list of clinically relevant topics and 
questions pertaining to the treatment of schizophrenia 
with cariprazine in the real world. Third, the panel par-
ticipants met in person and were asked to discuss the 
topics above and offered to add other question or topic 
that they felt was clinically relevant for real-world treat-
ment of schizophrenia with cariprazine. The final survey, 
included the following topics: (1) place in therapy and 
clinical characteristics of patient populations treated with 
cariprazine by panel members in their respective clini-
cal centres (both in- and out-patient facilities); (2) most 
frequently used doses of cariprazine in their practice; (3) 
procedures used in switching from other antipsychot-
ics to cariprazine, up-titration and time to observation 
of beneficial effects: acute/maintenance treatment; (4) 
use of concomitant medications and duration of therapy 
by patient group/setting; (5) combination treatment; (6) 
nature, incidence and management of adverse events and 
the role of treatment adjustment/withdrawal; and (7) 
recommendations to individualize cariprazine treatment 
for patients with schizophrenia. Each of the thematically 
defined discussions was supplemented by systematically 
evaluations and ratings of the proposed topics. A number 
of the questions included Likert scales (0–10) and free 
text replies to measure opinions, perceptions, and behav-
iours. Clinicians completed questionnaires electronically, 
during the in person meeting, and answers were stored 
remotely for analysis. All completed answers were elec-
tronically and anonymously recorded during the meet-
ing, and no demographic data were collected.
Results: Data gathering and recommendations
Cariprazine: place in therapy, patient characteristics
What are the most frequent clinical conditions for which 
you use cariprazine in your clinic?
The panel members indicated use of cariprazine in 
patients with a wide spectrum of presenting symptoms 
or conditions (Table 1). Cariprazine was most often pre-
scribed for patients presenting with their first episode of 
psychosis—in general these tend to be younger patients; 
sufficient clinical experience with cariprazine in elderly 
patients (over 65 years) was not reported. The two other 
major groups considered to be ‘first-line candidates’ 
for cariprazine are those with predominantly negative 
symptoms and those with metabolic syndrome includ-
ing ethnic groups/non-caucasians with diverse metabolic 
profiles.
Most frequently used doses of cariprazine in clinical 
practice
What are the most frequently used doses of caripra-
zine in your clinic? For patients with a first episode of 
psychosis the general consensus was that the majority 
of patients can be successfully managed on 1.5–3.0  mg 
but this depends on several issues, such as severity of 
symptoms and setting of treatment (community/in 
patients), with more severe symptoms often requiring 
higher doses, and other patient characteristics, for exam-
ple BMI (higher BMI usually requires longer periods to 
Table 1 Spectrum of  presenting conditions for  which 
Panel prescribed cariprazine in their practice (in- and out-
patients)
First episode of psychosis
Positive symptoms
Negative symptoms
Patients with schizophrenia spectrum disorders and agitation (in combi‑
nation with a second medication, e.g., a benzodiazepine)
Patients with schizophrenia spectrum disorders and metabolic syndrome
Patients with schizophrenia spectrum disorders and substance use 
disorder
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achieve steady state and hence therapeutical levels and 
may require a faster titration schedule or higher initial 
dose, to attain an earlier achievement of the therapeutical 
blood concentrations). When severe symptoms are pre-
sent, there is usually a need to quickly achieve a higher 
dose (4.5/6 mg). The panel judged that patients with agi-
tation who are treated with cariprazine very often need 
adjunctive treatment with a benzodiazepine or another 
sedating agent (See: “Use of concomitant medication and 
duration of therapy by patient group/setting”—patients 
with insomnia or agitation). In those cases, cariprazine is 
usually needed at doses of 4.5–6 mg. If side effects such 
as akathisia appear, the dosage should be reduced (See: 
“Nature, incidence and management of side effects and 
the role of treatment adjustment/withdrawal” section). 
When cariprazine is used to treat a patient with schizo-
phrenia and acute agitation, the advantage is that it can 
be continued long-term thus avoiding the need to start 
with a sedative antipsychotic drug and then switch treat-
ment after the acute phase has passed. The majority of 
the panel considered that treatment-resistant patients 
require the highest dosage (6.0  mg). A large portion of 
physicians reported improvements in symptoms with 
3.0 mg, in particular favourable long-term effects on neg-
ative symptoms with 3.0 mg without the need to increase 
the dosage. The possibility of using therapeutic drug 
monitoring (TDM) for dose optimization and to respond 
to individual differences during the course of therapy 
were mentioned. Figure  1 reports cariprazine dosages 
used by Panel to treat schizophrenia in their clinical prac-
tice (Fig. 1).
Procedures used in switching from other antipsychotics 
to cariprazine, up‑titration and time to observation 
of beneficial effects: acute/maintenance treatment
The overriding consideration in switching stable patients 
who need to change medication because of side effects, 
or to better deal with residual negative symptoms/cogni-
tive disabilities, is to avoid relapse and the panel were in 
agreement of the need to ensure that an effective dose of 
cariprazine is reached before tapering. In some cases, the 
risk of increased side effects is offset by avoiding relapse, 
but it is important to obtain a balance. The long-half life 
of cariprazine gave reason to the opinion that it can be 
up-titrated quickly followed by final adjustments of daily 
dose, while blood levels gradually increase, up to steady 
state according to previous pharmacokinetic investiga-
tions. After multiple dose administration mean caripra-
zine and DCAR concentrations reached steady state at 
around weeks 1–2 and mean DDCAR levels approached 
steady state at around weeks 4–8, in a 12-week study 
[16]. Using the half-life of total cariprazine (the sum of 
cariprazine and its major active metabolites DCAR, and 
DDCAR) a time marker of 3 weeks for a steady state has 
been estimated. Population pharmacokinetic/pharma-
codynamic modelling has been used to investigate the 
longitudinal exposure‐response relationship for total 
cariprazine in patients enrolled in the clinical devel-
opment program. Total cariprazine exposure was sig-
nificantly related to reductions in Positive and Negative 
Syndrome Scale (PANSS) total scores and typical steady‐
state plasma concentrations after 3.0 and 4.5  mg/day 
were associated with 50% of maximum typical reductions 
in PANSS scores [17].
Clinicians reported that they usually introduce caripra-
zine while slowly reducing other antipsychotics (if 
Fig. 1 Cariprazine dosages used by Panel (%) to treat schizophrenia in their clinical practice
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taking). The length of time in switching depends on the 
type of drug(s) the patient has already been prescribed 
and TDM may be useful for dose optimization. In the 
panel’s experience switching from the partial agonist 
aripiprazole can be done in 1  week or less but a longer 
overlapping time is necessary when switching from med-
ications such as risperidone or haloperidol. Care must be 
taken when down-titrating medications with pronounced 
antihistaminergic/antimuscarinic effects like olanzap-
ine, quetiapine or clozapine. In stable patients, switching 
from risperidone is not usually associated with hista-
minergic/muscarinic rebound. However, a dopaminer-
gic rebound is possible and hence an overlap of at least 
2–3 weeks is usually recommended. If the patient is sta-
ble and treated with olanzapine, quetiapine or clozapine, 
the switch will be usually performed over a longer time 
period (3–4  weeks) owing to the risk of both antihista-
minergic/muscarinic and dopaminergic rebound. Over-
lapping ‘plateau’ switch strategies (the effective blood 
concentration of the new drug is reached before reduc-
ing/stopping the other one) and transient co-treatment 
with medications, such as benzodiazepines (e.g., loraz-
epam 1-4  mg/day) are used to overcome the rebound 
phenomena that can complicate the early switch period. 
The time employed in up-titration of cariprazine depends 
to some extent on the setting and practical issues—in the 
acute setting it is usually performed faster than in out-
patient clinics according to the frequency of visitation 
as well as due to different urgencies of the clinical situ-
ations (Table 2). With outpatients who may be seen less 
frequently, it takes longer to up-titrate/switch with medi-
cations with long-half life. A portion of patients, around 
25%, experience akathisia when switching to cariprazine 
which decreases the likelihood of a successful switch-
as patients are reluctant to continue. In these cases, the 
dosage is increased in a stepwise fashion at longer (e.g., 
2-week) intervals. This takes longer but improves efficacy 
and adherence in the long-term (See: “Nature, incidence 
and management of side effects and the role of treatment 
adjustment/withdrawal” section). The time to observe 
beneficial effects depends on the patient and the dosage 
used: improvements are observed in around 1 month for 
positive symptoms, but complex negative symptoms take 
up to 6 months and longer to improve.
Use of concomitant medications and duration of therapy 
by patient group/setting
Patients with insomnia or agitation
A cross section of responders would prescribe a ben-
zodiazepine to treat insomnia but for some the use of a 
benzodiazepine depends on the setting and the risk of 
addiction and other side effects, such as paradoxical acti-
vation, sedation, falls, and withdrawal symptoms if the 
medication is discontinued too quickly (Fig. 2a). Antide-
pressants, such as mirtazapine or trazodone, or sedating 
antipsychotics at low doses, may be alternatives to a ben-
zodiazepine. Similarly, to manage concomitant agitation 
the group were distributed as to add a benzodiazepine 
(which had the highest score) or a second sedating antip-
sychotic/antidepressant agent but not at antipsychotic 
doses, or to avoid using two antipsychotics, i.e., discon-
tinue cariprazine and change antipsychotic (Fig. 2b).
Partial response to positive or negative symptoms
In patients showing partial responses to positive symp-
toms after treatment with cariprazine for a period of 
2–3 weeks, one option is to increase the dose of caripra-
zine to the highest dosage. If this is not adequate another 
antipsychotic is added (Fig.  3a). Similarly, if there is a 
partial response for negative symptoms—the dose can 
be increased and/or add an antidepressant and/or add/
switch to another antipsychotic (Fig.  3b). The role of 
non-pharmacological therapies should, however, not 
be underestimated—if there is a partial response for 
Table 2 Up-titration with cariprazine in acute and maintenance settings
Fast
Acute
Slow
Maintenance
In acute setting up‑titrate to 4.5 mg or 6.0 mg in 1 week—increase 1.5 mg 
every day up to 6.0 mg if no side effects manifest
Up‑titration should be slow in maintenance, whereas fast titration is not 
necessary in maintenance
Fast titration appropriate for hospital setting due to the need to shorten the 
length of stay in the hospital
Stopping in case of side effects 1 week if replaced with another neu‑
roleptic. Reducing dose in case of beginning of metabolic problems, 
stop immediately in case of worsening psychotic feature (positive 
symptoms)
Side effects may delay up‑titration, but goal is to reach effective dose as soon 
as possible
The slower the better if side effects such as akathisia manifest
When used as monotherapy in highly ‘acute’ cases fast up‑titration required If body weight is over 120 kg should start with the 3.0 mg dosage
Switch 1.5 mg every 3 days is acceptable and usually less likely to produce 
akathisia
Vulnerable patients must be titrated much slower
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negative symptoms then the patient can be motivated 
to start psychotherapies or rehabilitation interventions 
such as cognitive rehabilitation and social skills training, 
which then can have a synergistic/additive effect.
Combination therapy
The panel reported that cariprazine monotherapy is 
indicated for patients with schizophrenia spectrum dis-
orders. However, for partial responses and patients with 
comorbidities (schizoaffective disorder, agitation, aggres-
sion, substance abuse) combinations may be necessary 
(Fig.  4). It is important to ensure drug interactions do 
not occur to avoid side effects such as dizziness, drowsi-
ness, confusion, and difficulty concentrating. Also, it is 
not advisable to use carbamazepine, or another CYP3A4 
inducer, in combination with cariprazine; moreover, cli-
nicians should evaluate very carefully adding valproic 
acid in females, due to the teratogenic risk. Cariprazine 
can be given in combination with lithium in patients at 
risk of suicide.
Nature, incidence and management of side effects 
and the role of treatment adjustment/withdrawal
The most common and clinically bothersome adverse 
event with cariprazine is akathisia (Fig.  5). Increase in 
body weight, metabolic syndromes and cardiovascular 
changes are not reported to be particularly problematic. 
In many cases, when cariprazine is discontinued it is 
not due to lack of efficacy but adverse events which are 
patient dependent. In most cases adverse events are suc-
cessfully managed by dosage reductions or, in the case of 
acute akathisia, short-term combination with a benzodi-
azepine or beta-blocker.
Recommendations to individualize cariprazine treatment 
for patients with schizophrenia
Due to the specific pharmacodynamics profile, (partial 
agonist of the dopamine receptors D2/D3, with a ten-
fold affinity for the D3 receptor with partial agonism for 
the serotonin [5-hydroxytryptamine] 5HT1A receptor, 
as well as antagonism at 5HT2B and 5HT2A receptors 
Fig. 2 Medications used by Panel to treat concomitant insomnia (a) and agitation (b)
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Fig. 3 Strategies employed when there is a partial response for positive symptoms (a) and negative symptoms (b)
Fig. 4 Frequency (%) of cariprazine as monotherapy and in combination
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and for the histamine H1 receptor), the panel members 
judge cariprazine to be a drug with important clinical 
and pharmacological advantages over other antipsychotic 
agents [17, 19–21]. The main advantage is assumed in 
its superior efficacy in treating the negative symptoms 
of schizophrenia—representing a major step forward 
for patients, carers and healthcare professionals alike 
[22, 23]. The panel noted the evidence on the ability of 
cariprazine to reduce troublesome side-effects that fre-
quently cause patients to discontinue some of the other 
antipsychotics, including anti-cholinergic (dry mouth, 
constipation, urinary retention, exacerbation of the 
dangerous effects of closed-angle glaucoma), anti-adren-
ergic (orthostatic hypotension), antihistaminergic (seda-
tion, weight gain) and metabolic (weight gain, increased 
cholesterol, increased triglycerides) as well as a reduced 
risk of arrhythmias [24, 25].
The panel recommended patients with negative symp-
toms—which are among the most debilitating aspects of 
schizophrenia—as a target group for cariprazine (Fig. 6) 
[26]. The importance of preparing a long-term treatment 
plan is sometimes lost sight of, in particular when rele-
vant acute positive symptoms triggered the initial treat-
ment decisions. If the initial antipsychotic strategy does 
Fig. 5 Side effects (%) most commonly observed in physicians’ everyday clinical practice
Fig. 6 Patients groups the Panel considered would benefit treatment with cariprazine
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not significantly improve negative symptoms, a medica-
tion switch may be necessary once the positive symptoms 
are treated. In many situations healthcare professionals 
concentrate on the acute phase of schizophrenia (psy-
choses), because it is the most ‘urgent’ but the resolu-
tion of negative symptoms or of side effects is just being 
postponed. Furthermore, sedation is a major issue in the 
management of schizophrenia—it may be welcomed in 
the acute phase but is detrimental in the long-term as 
it prevents patients from functioning and focusing on 
the future and in some cases causes patients to be non-
adherent. Schizophrenia patients with metabolic issues 
are dying 15  years earlier, inter alia, due to metabolic 
issues so a drug such as cariprazine with a low level of 
metabolic problems—there has been a recent report of 
a reversal of the metabolic syndrome with cariprazine—
represents a major advance in the management of this 
patient group [27].
When cariprazine is administered at the outset to first 
psychotic episode patients (acute/in-patients/in the com-
munity) to control both positive and negative symptoms, 
the need for a switch once positive symptoms are con-
trolled might be lower (Fig. 6).
Another patient group in whom the panel considered 
cariprazine can make a difference is in patients with 
schizophrenia and concomitant substance use disor-
der. A large portion of the patients the panel see with 
schizophrenia also consume illicit drugs and there are 
limited treatment choices that can make a difference. If 
a patient continues to, for example, smoke cannabis, is 
non-adherent or partially adherent and does not want 
to take a depot formulation, the long-half life and non-
sedative action of cariprazine make it the drug of choice. 
Cravings are a part of the ongoing cycle of addiction 
and certain agents can prevent cravings (illicit drugs/
alcohol) by blocking the receptors (e g., NMDA-, opioid- 
and dopamine receptors) associated with cues that set 
off relapse—cariprazine is a partial agonist at dopamine 
D2/D3 receptors and as such may have a role in reduc-
ing cravings in schizophrenia patients with substance use 
disorder [28–30]. In an animal study, cariprazine outper-
formed aripiprazole in decreasing the rewarding effect of 
cocaine and avoiding relapse after a period of withdrawal 
from cocaine and related cues [31]. Patients with mild or 
moderate agitation may benefit from cariprazine, pro-
vided that a second agent (such as lorazepam) is added. 
The panel considered that cariprazine is not a first choice 
for patients with severe agitation (Fig. 6).
Combinations of antipsychotics are commonly used 
in refractory schizophrenia when a single agent does 
not relieve symptoms adequately, but there is limited 
evidence on the benefits of this strategy. Cariprazine 
improves social functioning and as such may have a 
place as an add-on therapy (at low dosages) in treatment-
resistant patients, including those on clozapine or on 
long acting antipsychotics (LAI). To our knowledge, no 
randomized controlled trials testing the combination of 
cariprazine and clozapine or cariprazine and LAI have 
been conducted to date. Indeed, the results from meta-
analyses of antipsychotic combinations indicate that data 
are insufficient and that more studies are needed. How-
ever, a recent paper by Guinart and Correl, evaluated 
the existing evidence and concluded that ‘evidence for 
superior efficacy vs antipsychotic monotherapy is scant 
(possibly with the exception of reductions in negative 
symptoms when combining a partial D2  agonist and a 
D2 antagonist)’ [32]. Hence, the combination clozapine–
cariprazine or LAI cariprazine is of interest, especially 
for cases of patients with treatment-resistant schizophre-
nia that do not respond to more supported treatments 
[32–34].
Conclusions
According to the panel’s collective experience and opin-
ions, the ideal cariprazine patients are individuals at their 
first episodes of psychosis, those with predominant nega-
tive symptoms during the maintenance period or during 
the acute phase, and those with significant side effects 
(i.e., metabolic side effects, hyperprolactinemia, or seda-
tion) from other antipsychotics during periods of stabil-
ity. Cariprazine may also be a drug of choice for patients 
with predominant positive symptoms during the acute 
phase, especially when clinicians consider the longer 
term benefits. When schizophrenia is seen as a life-long 
disorder, characterized by relatively brief periods of exac-
erbation and relatively longer periods of remission, the 
goal of treating acute symptoms remains paramount. 
However, in these cases, the efficacy in treating negative 
symptoms and the tolerability profile become as impor-
tant as the need to treat and prevent the positive and 
most acute symptoms. When the long-term treatment 
of a lifetime illness is adequately weighted, cariprazine 
becomes one of the first-line medications, not only for 
first episode patients, patients with predominant negative 
symptoms and those with significant side effects from 
other antipsychotics but also for patients with relatively 
severe positive symptoms. When positive symptoms are 
very severe, adjunctive medications may be necessary, at 
least for the acute treatment period. In fact, the favour-
able effectiveness during the maintenance period may 
drive the choice in the acute phase, even at the price of 
using a second medication. For instance, in a patient 
with moderate agitation, a clinician looking exclusively at 
the acute phase would likely choose a sedating antipsy-
chotic, such as olanzapine, that successfully treats all the 
symptoms discussed above in most patients. However, a 
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clinician that looks at the maintenance treatment as well, 
may rather choose a medication like cariprazine aug-
mented with a benzodiazepine or another medication 
that is effective for agitation. In fact, cariprazine is usu-
ally better tolerated than olanzapine, primarily in terms 
of metabolic side effects, and the benzodiazepine can be 
discontinued afterwards, when the control of agitation is 
no longer necessary.
The same may be true when a clinician chooses to aug-
ment clozapine with an antipsychotic such as cariprazine, 
when a patient is experiencing inefficacy of clozapine 
for negative symptoms. In some of these cases, once the 
patient is stabilised, it is then possible to decrease the 
clozapine dose. In a smaller yet significant number of 
cases, it may even be possible to completely discontinue 
clozapine, after a long enough period of stability, leaving 
the patient on a better tolerated antipsychotic. Likewise, 
when a patient experiences psychotic symptoms in the 
acute phase that are partially resistant to cariprazine, a 
clinician can choose to use it in combination with clozap-
ine or risperidone.
Based on their real-world clinical experience the panel 
considered that cariprazine, with its distinct advantages 
including pharmacokinetics, pharmacodynamics, efficacy 
and tolerability, represents one of the drugs of choice in 
the long-term management of schizophrenia not only for 
patients with predominant negative symptoms but also 
for those with positive symptoms. When positive symp-
toms are severe and partially responding to cariprazine, 
the combination of cariprazine with a second antipsy-
chotic may be considered, with the goal to attempt mon-
otherapy once the acute phase has solved and the patient 
progresses to maintenance treatment.
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